Clinical Trial Search Results
'Inventiva S.A. / “A randomised, double-blind, placebo- controlled, multicentre, Phase 3 study evaluating long-term efficacy and safety of lanifibranor in adult patients with non-cirrhotic non-alcoholic steatohepatitis (NASH) and fibrosis 2 (F2)/fibrosis 3 (F3) stage of liver fibrosis”
'
'
This study is currently enrolling.
Inventiva S.A. (the Sponsor) is running a research study to see if an investigational drug named lanifibranor, not yet approved for marketing, will help in the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH) and ...
5-Hydroxymethylation Patterns in cDNA from Patients Presenting with Suspicion of Ovarian Carcinoma
This study is currently enrolling.
The purpose of this research is to see if we can identify any markers in the blood which might be able to be used in a screening test for cancer. We are also interested in studying the changes in the blood over time of patients ...
A double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of intravenous ganaxolone in status epilepticus
This study is currently enrolling.
The purpose of this research is to find out if ganaxolone can stop or decrease the seizure activity in participants who have SE and if ganaxolone is safe compared to placebo when given to participants who are on other anti-seiz ...
A Double-blind, Randomized, Placebo-controlled, Multicenter Study
Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with
Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with
Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
This study is currently enrolling.
Study 20180244 is a double-blind, randomized, placebo-controlled, multicenter outcomes study to assess the impact of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD) and e ...
A Multi-center, Randomized, Double-blind, Placebo controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A
This study is currently enrolling.
The main purpose of this study is to investigate how effective PXT3003 is when compared to a placebo, on the disease progression and symptoms of CMT1A. The study also aims to assess the safety and tolerability (whether side ef ...
A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients with Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy
This study is currently enrolling.
The aim of this study is to assess the safety and effectiveness of the study drug, TTAC-0001 to patients with recurrent glioblastoma which has progressed on bevacizumab treatment. Another aim is to measure the levels of TTAC-00 ...
A Partially-Blind, Randomized, Controlled, Parallel-Group Dose Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact (SF-RI 1 surfactant for inhalation combined with a dedicated drug delivery system) in Preterm Infant at Risk of Worsening Respiratory Distress Syndrome
This study is currently enrolling.
The goal of this study is to see if giving surfactant as an aerosol to babies while they are on nCPAP or nIMV will decrease their need to be placed on a ventilator and receive surfactant through a breathing tube or through a ca ...
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors.
This study is currently enrolling.
The purpose of this study is to see if the study drug is safe and able to treat patients who have certain types of cancers, including solid tumors, triple negative breast cancer, pancreatic cancer, urothelial cancer, hepatocell ...
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies
This study is currently enrolling.
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated gamma delta T-cell therapy, in Adult Subjects with Relapsed/Refractory CD20-expressing B-cell Malignancies